Skip to main content
NASDAQ:PRTG

Portage Biotech Competitors

$28.39
+0.35 (+1.25 %)
(As of 05/14/2021 01:26 PM ET)
Add
Compare
Today's Range
$28.25
$28.65
50-Day Range
$26.99
$31.00
52-Week Range
$8.65
$41.41
Volume210 shs
Average Volume11,122 shs
Market Capitalization$343.04 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Portage Biotech (NASDAQ:PRTG) Vs. CGEM, EWTX, NRIX, KNTE, CNTB, and SBTX

Should you be buying PRTG stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Portage Biotech, including Cullinan Oncology (CGEM), Edgewise Therapeutics (EWTX), Nurix Therapeutics (NRIX), Kinnate Biopharma (KNTE), Connect Biopharma (CNTB), and Silverback Therapeutics (SBTX).

Portage Biotech (NASDAQ:PRTG) and Cullinan Oncology (NASDAQ:CGEM) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Portage Biotech and Cullinan Oncology, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Portage Biotech0000N/A
Cullinan Oncology00403.00

Cullinan Oncology has a consensus price target of $48.75, suggesting a potential upside of 76.63%. Given Cullinan Oncology's higher possible upside, analysts clearly believe Cullinan Oncology is more favorable than Portage Biotech.

Valuation & Earnings

This table compares Portage Biotech and Cullinan Oncology's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Portage BiotechN/AN/AN/AN/AN/A
Cullinan OncologyN/AN/AN/AN/AN/A

Profitability

This table compares Portage Biotech and Cullinan Oncology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Portage BiotechN/AN/AN/A
Cullinan OncologyN/AN/AN/A

Summary

Cullinan Oncology beats Portage Biotech on 2 of the 2 factors compared between the two stocks.

Portage Biotech (NASDAQ:PRTG) and Edgewise Therapeutics (NASDAQ:EWTX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, institutional ownership, dividends and valuation.

Profitability

This table compares Portage Biotech and Edgewise Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Portage BiotechN/AN/AN/A
Edgewise TherapeuticsN/AN/AN/A

Analyst Recommendations

This is a summary of current recommendations and price targets for Portage Biotech and Edgewise Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Portage Biotech0000N/A
Edgewise Therapeutics01302.75

Edgewise Therapeutics has a consensus price target of $34.25, indicating a potential upside of 26.34%. Given Edgewise Therapeutics' higher probable upside, analysts clearly believe Edgewise Therapeutics is more favorable than Portage Biotech.

Valuation & Earnings

This table compares Portage Biotech and Edgewise Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Portage BiotechN/AN/AN/AN/AN/A
Edgewise TherapeuticsN/AN/AN/AN/AN/A

Summary

Edgewise Therapeutics beats Portage Biotech on 2 of the 2 factors compared between the two stocks.

Portage Biotech (NASDAQ:PRTG) and Nurix Therapeutics (NASDAQ:NRIX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, profitability, analyst recommendations, risk and institutional ownership.

Insider & Institutional Ownership

82.0% of Nurix Therapeutics shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Portage Biotech and Nurix Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Portage BiotechN/AN/AN/AN/AN/A
Nurix TherapeuticsN/AN/AN/AN/AN/A

Analyst Recommendations

This is a summary of recent ratings and price targets for Portage Biotech and Nurix Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Portage Biotech0000N/A
Nurix Therapeutics00703.00

Nurix Therapeutics has a consensus price target of $46.00, indicating a potential upside of 76.86%. Given Nurix Therapeutics' higher possible upside, analysts clearly believe Nurix Therapeutics is more favorable than Portage Biotech.

Profitability

This table compares Portage Biotech and Nurix Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Portage BiotechN/AN/AN/A
Nurix TherapeuticsN/AN/AN/A

Summary

Nurix Therapeutics beats Portage Biotech on 3 of the 3 factors compared between the two stocks.

Portage Biotech (NASDAQ:PRTG) and Kinnate Biopharma (NASDAQ:KNTE) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, risk, profitability, institutional ownership, earnings and dividends.

Profitability

This table compares Portage Biotech and Kinnate Biopharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Portage BiotechN/AN/AN/A
Kinnate BiopharmaN/AN/AN/A

Earnings and Valuation

This table compares Portage Biotech and Kinnate Biopharma's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Portage BiotechN/AN/AN/AN/AN/A
Kinnate BiopharmaN/AN/AN/AN/AN/A

Analyst Recommendations

This is a summary of recent recommendations for Portage Biotech and Kinnate Biopharma, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Portage Biotech0000N/A
Kinnate Biopharma00403.00

Kinnate Biopharma has a consensus price target of $52.00, indicating a potential upside of 126.88%. Given Kinnate Biopharma's higher probable upside, analysts clearly believe Kinnate Biopharma is more favorable than Portage Biotech.

Summary

Kinnate Biopharma beats Portage Biotech on 2 of the 2 factors compared between the two stocks.

Connect Biopharma (NASDAQ:CNTB) and Portage Biotech (NASDAQ:PRTG) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations and dividends.

Analyst Recommendations

This is a summary of current recommendations and price targets for Connect Biopharma and Portage Biotech, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Connect Biopharma00303.00
Portage Biotech0000N/A

Connect Biopharma currently has a consensus price target of $29.50, suggesting a potential upside of 82.10%. Given Connect Biopharma's higher possible upside, equities analysts clearly believe Connect Biopharma is more favorable than Portage Biotech.

Profitability

This table compares Connect Biopharma and Portage Biotech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Connect BiopharmaN/AN/AN/A
Portage BiotechN/AN/AN/A

Valuation and Earnings

This table compares Connect Biopharma and Portage Biotech's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Connect BiopharmaN/AN/AN/AN/AN/A
Portage BiotechN/AN/AN/AN/AN/A

Summary

Connect Biopharma beats Portage Biotech on 2 of the 2 factors compared between the two stocks.

Portage Biotech (NASDAQ:PRTG) and Silverback Therapeutics (NASDAQ:SBTX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, valuation, analyst recommendations, risk, institutional ownership and dividends.

Profitability

This table compares Portage Biotech and Silverback Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Portage BiotechN/AN/AN/A
Silverback TherapeuticsN/AN/AN/A

Earnings and Valuation

This table compares Portage Biotech and Silverback Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Portage BiotechN/AN/AN/AN/AN/A
Silverback TherapeuticsN/AN/AN/AN/AN/A

Analyst Ratings

This is a summary of recent ratings and price targets for Portage Biotech and Silverback Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Portage Biotech0000N/A
Silverback Therapeutics00403.00

Silverback Therapeutics has a consensus target price of $50.25, indicating a potential upside of 79.59%. Given Silverback Therapeutics' higher probable upside, analysts plainly believe Silverback Therapeutics is more favorable than Portage Biotech.

Summary

Silverback Therapeutics beats Portage Biotech on 2 of the 2 factors compared between the two stocks.


Portage Biotech Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Cullinan Oncology logo
CGEM
Cullinan Oncology
1.4$27.41+1.2%$1.21 billionN/A0.00News Coverage
EWTX
Edgewise Therapeutics
1.8$26.76+5.9%$1.20 billionN/A0.00
Nurix Therapeutics logo
NRIX
Nurix Therapeutics
2.0$25.60+1.6%$1.12 billionN/A0.00
KNTE
Kinnate Biopharma
1.7$22.66+2.1%$964.98 millionN/A0.00News Coverage
Gap Up
CNTB
Connect Biopharma
1.7$16.20+4.3%$891.31 millionN/A0.00
Silverback Therapeutics logo
SBTX
Silverback Therapeutics
1.7$27.78+11.1%$862.45 millionN/A0.00Earnings Announcement
News Coverage
Gap Up
STEM
Stem
0.0$17.81+8.0%$785.39 millionN/A0.00Gap Up
iTeos Therapeutics logo
ITOS
iTeos Therapeutics
1.9$23.00+2.8%$784.86 millionN/A0.00Earnings Announcement
Analyst Report
News Coverage
Pharming Group logo
PHAR
Pharming Group
0.0$12.15+2.0%$763.78 millionN/A0.00News Coverage
Gap Down
Vor Biopharma logo
VOR
Vor Biopharma
1.5$18.95+4.0%$731.50 millionN/A0.00Analyst Upgrade
Gap Up
Pharvaris B.V. logo
PHVS
Pharvaris B.V.
1.5$22.25+0.0%$708.44 millionN/A0.00Gap Up
FDMT
4D Molecular Therapeutics
1.3$26.70+1.0%$705.26 millionN/A0.00Earnings Announcement
News Coverage
Bolt Biotherapeutics logo
BOLT
Bolt Biotherapeutics
1.3$18.30+0.2%$665.89 millionN/A0.00Gap Down
Gracell Biotechnologies logo
GRCL
Gracell Biotechnologies
1.4$10.42+6.4%$655.33 millionN/A0.00News Coverage
Gap Up
FNCH
Finch Therapeutics Group
2.0$12.12+0.7%$567.15 millionN/A0.00
Inventiva logo
IVA
Inventiva
1.4$14.15+1.1%$546.61 millionN/A0.00
VACC
Vaccitech
0.3$16.97+7.2%$536.51 millionN/A0.00News Coverage
Gap Up
ACHL
Achilles Therapeutics
1.6$13.65+7.6%$512.24 millionN/A0.00Earnings Announcement
Quiet Period Expiration
Analyst Revision
Gap Up
MIGI
Mawson Infrastructure Group
0.0$0.89+6.7%$471.73 millionN/A0.00Upcoming Earnings
BMEA
Biomea Fusion
1.7$16.60+4.2%$457.70 millionN/A0.00Analyst Report
Analyst Revision
News Coverage
Gap Up
VECT
VectivBio
1.6$12.88+1.5%$431.65 millionN/A0.00Quiet Period Expiration
SGTX
Sigilon Therapeutics
1.4$13.25+6.0%$417.77 millionN/A0.00Earnings Announcement
Analyst Revision
News Coverage
Angion Biomedica logo
ANGN
Angion Biomedica
1.6$14.24+1.7%$412.78 millionN/A0.00Gap Down
Landos Biopharma logo
LABP
Landos Biopharma
1.5$11.18+8.8%$409.20 millionN/A0.00
RAIN
Rain Therapeutics
1.3$15.23+1.0%$391.61 millionN/A0.00
NexImmune logo
NEXI
NexImmune
2.0$17.38+1.3%$390.30 millionN/A0.00Gap Down
Terns Pharmaceuticals logo
TERN
Terns Pharmaceuticals
1.7$16.10+5.8%$380.90 millionN/A0.00
Gemini Therapeutics logo
GMTX
Gemini Therapeutics
1.7$9.53+9.5%$370.65 millionN/A0.00News Coverage
Gap Up
HOWL
Werewolf Therapeutics
0.3$11.59+0.1%$319.45 millionN/A0.00Gap Up
Sensei Biotherapeutics logo
SNSE
Sensei Biotherapeutics
2.0$9.61+6.1%$312.00 millionN/A0.00Earnings Announcement
Analyst Revision
News Coverage
IMPL
Impel NeuroPharma
0.3$13.69+1.9%$270.84 millionN/A0.00
Kaleido Biosciences logo
KLDO
Kaleido Biosciences
1.5$6.53+10.9%$247.46 millionN/A-2.58
Unity Biotechnology logo
UBX
Unity Biotechnology
1.3$4.24+0.5%$233.40 millionN/A-2.26Earnings Announcement
VINC
Vincerx Pharma
1.0$16.91+3.4%$228.50 millionN/A0.00
RPHM
Reneo Pharmaceuticals
2.0$8.20+2.3%$193.93 millionN/A0.00Quiet Period Expiration
Gap Up
Annovis Bio logo
ANVS
Annovis Bio
1.7$23.65+1.6%$161.73 millionN/A0.00Upcoming Earnings
Analyst Report
News Coverage
Gap Up
Decibel Therapeutics logo
DBTX
Decibel Therapeutics
2.1$7.16+10.8%$159.12 millionN/A0.00Earnings Announcement
Analyst Downgrade
News Coverage
Gap Up
LBPH
Longboard Pharmaceuticals
1.9$8.58+2.1%$148.19 millionN/A0.00
ImmunoPrecise Antibodies logo
IPA
ImmunoPrecise Antibodies
0.0$7.93+5.4%$143.77 millionN/A0.00Gap Up
GANX
Gain Therapeutics
1.7$9.79+8.1%$106.89 millionN/A0.00Gap Up
EVAX
Evaxion Biotech A/S
1.7$5.30+5.7%$101.76 millionN/A0.00News Coverage
Gap Up
Trading Halted
LGVN
Longeveron
0.0$5.20+1.9%$98.58 millionN/A0.00News Coverage
VRDN
Viridian Therapeutics
1.7$17.52+3.8%$68.47 millionN/A0.00News Coverage
Gap Up
UPC
Universe Pharmaceuticals
0.0$3.20+3.4%$67.21 millionN/A0.00Gap Up
Inhibikase Therapeutics logo
IKT
Inhibikase Therapeutics
1.0$4.60+6.5%$49.29 millionN/A0.00Gap Down
CUBT
Curative Biotechnology
0.0$0.11+8.7%$44.64 millionN/A0.00Gap Up
Viracta Therapeutics logo
VIRX
Viracta Therapeutics
1.5$7.65+0.1%$39.63 millionN/A0.00Analyst Downgrade
Gap Up
VIRI
Virios Therapeutics
1.3$4.71+2.1%$39.23 millionN/A0.00News Coverage
CMMB
Chemomab Therapeutics
1.7$17.41+4.7%$38.77 millionN/A0.00Earnings Announcement
Analyst Report
News Coverage
Gap Up
NLS Pharmaceutics logo
NLSP
NLS Pharmaceutics
1.7$3.43+6.7%$37.69 millionN/A0.00Gap Up
This page was last updated on 5/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.